Mineralys Therapeutics, Inc. MLYS 深 滬
等待開盤 09-11 09:30:00 美东时间
37.47
-1.030
-2.68%
華盛通- 最 高38.57
- 今 開38.50
- 成交量 124.32万股
- 最 低 35.00
- 昨 收 38.50
- 總市值 24.84亿
- 52周最高 38.57
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 8.241
- 委 比 -92.35%
- 總股本 6629.52万
- 歷史最高 38.57
- 量 比 0.56
- 振 幅 9.27%
- 歷史最低 5.85
- 每 手 1
- 風險率 3.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
美股大行评级 | 潜在涨幅37.57%！Mama's Creations获Roth Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持Mama's Creations"买入"评级，目标价从10美元升至13美元；高盛：维持Mineralys Therapeutics"买入"评级，目标价从32美元升至52美元
09-10 09:47
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Mineralys Therapeutics announced positive subgroup analysis from the Phase 3 Launch-HTN trial of lorundrostat, demonstrating significant blood pressure reduction across diverse high-risk populations, including Black/African American adults, older adults, women, and those with obesity, with a favorable safety profile. The trial, the largest in uncontrolled or resistant hypertension, enrolled 1,083 participants on 2-5 antihypertensives, achieving r...
09-05 13:00
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mineralys Therapeutics completed an underwritten public offering of 11,274,509 shares, including an additional 1,470,588 shares, at $25.50 per share, raising approximately $287.5 million. The proceeds will fund clinical development of lorundrostat, manufacturing, and pre-commercialization activities. Major underwriters included BofA Securities, Evercore ISI, Goldman Sachs, Stifel, and Wells Fargo Securities. The offering was conducted under SEC-r...
09-04 20:01
Mineralys完成2.5亿美元股票发行定价
美股周三早盘，生物技术公司Mineralys Therapeutics（MLYS）股价下跌2.3%，此前该公司将其规模扩大后的2.5亿美元股票发行价格定为每...
09-03 22:38
美股牛股 | 医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%
医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%，实验性药物临床数据乐观；MLYS大涨逾80%，高血压新药市场前景广阔>>
09-03 15:53
Mineralys Therapeutics prices upsized $250M stock offering
Mineralys Therapeutics (NASDAQ:MLYS) priced an upsized underwritten public offering of 9.8M shares at a public offering price of $25.50 per share. The aggregate gross proceeds to Mineralys from the of...
09-03 13:39
Mineralys Therapeutics Suspends Prospectus Supplement For ATM Equity Offering
-SEC Filing
09-03 05:08
Mineralys Therapeutics launches $175M public offering
Mineralys Therapeutics (NASDAQ:MLYS) has commenced a $175M underwritten public offering of common stock. A 30-day option allows underwriters to purchase up to an additional $26.25M in shares. All shar...
09-03 04:17
